GB Sciences, Inc.
GBLX
$0.00
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 97.20K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 97.20K | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 97.20K | -- | -- | -- | -- |
| SG&A Expenses | 163.80K | 157.80K | 254.10K | 108.30K | 234.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.80K | 157.80K | 254.10K | 369.90K | 234.00K |
| Operating Income | -66.60K | -157.80K | -254.10K | -369.90K | -234.00K |
| Income Before Tax | -100.40K | -190.50K | -285.00K | -467.00K | -187.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.40K | -190.50K | -285.00K | -467.00K | -187.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.40K | -190.50K | -285.00K | -467.00K | -187.30K |
| EBIT | -66.60K | -157.80K | -254.10K | -369.90K | -234.00K |
| EBITDA | -66.40K | -157.60K | -254.00K | -369.90K | -234.00K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 407.07M | 407.07M | 406.57M | 406.00M | 403.17M |
| Average Diluted Shares Outstanding | 407.07M | 407.07M | 406.57M | 406.00M | 403.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |